A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy.

Su LiBingtian BiGuangyu LuoJing ZhanRong ZhangJibin LiNaisheng ChenJinling HuangJinping XueGuo-Liang Xu

Published in: Cancer chemotherapy and pharmacology (2020)

It is the first report of human trials of photocyanine, and the results suggested that patients receive 180 J/cm2 illumination about 20-30 min at serum concentrations of photocyanine between 1000 and 2500 ng/ml at least 10 h after administration.

Keyphrases

end stage renal disease
endothelial cells
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
randomized controlled trial
clinical trial
open label
induced pluripotent stem cells
data analysis
study protocol